BiotechTube
Actimed Therapeutics

Actimed Therapeutics

London, United Kingdom· Est.
actimedtherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

Actimed Therapeutics is a clinical-stage biotech pioneering treatments for cachexia and muscle wasting, a high-unmet-need area with no approved therapies. The company has a focused pipeline led by two clinical-stage assets, S-pindolol benzoate (ACM-001.1) and S-oxprenolol (ACM-002), repurposed enantiomers of existing beta-blockers. Recent strategic moves include a licensing agreement with Mankind Pharma and active data presentations at key medical conferences, positioning the company for potential partnerships and clinical advancement in a significant market opportunity.

CachexiaMuscle Wasting DisordersOncology Supportive CareMetabolic Disorders

Technology Platform

Stereoselective development of specific enantiomers (S-forms) of existing non-selective beta-blockers (e.g., pindolol, oxprenolol) to selectively target pathways involved in muscle preservation while minimizing cardiovascular effects.

Funding History

4
Total raised:$30M
Series A$10M
Series A$15M
Seed$2.5M
Seed$2.5M

Opportunities

The primary opportunity is addressing the vast, untreated market of cancer cachexia and other muscle-wasting conditions, which represents a multi-billion dollar potential.
Success with its lead candidate could establish a new standard of care and create a platform for expansion into related indications like sarcopenia and ALS.
Strategic partnerships, as evidenced by the Mankind Pharma deal, provide non-dilutive funding and a path to global commercialization.

Risk Factors

Key risks include clinical trial failure due to the complex and multifactorial nature of cachexia, regulatory uncertainty around endpoints and approval pathways, and the challenge of commercializing a first-in-class treatment for a condition that is often under-diagnosed.
The company remains dependent on raising additional capital to fund later-stage development.

Competitive Landscape

The competitive landscape for specific cachexia drugs is relatively sparse with no approved therapies, but includes several small biotechs and academic groups investigating diverse mechanisms (e.g., appetite stimulants, myostatin inhibitors, anti-inflammatories). Actimed's enantiomer-specific beta-blocker approach is a differentiated mechanism. Broader competition comes from supportive care measures like nutritional support and exercise.

More companies in Small Molecule Drugs →More companies in United Kingdom →